Parkinson Disease
📧 Sign up to get email alerts when something new happens for Parkinson Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-03-30Clinical Trial Update: Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects [Phase 1]
A Phase 1 pharmacokinetic study compares exposure of the drug BIA 6-512 between healthy elderly and healthy young subjects.
-
CLINICAL_TRIALS trial_result · 2017-03-30Clinical Trial Update: Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics [Phase 1]
Phase 1 trial assessing the effect of steady-state BIA 6-512 on levodopa pharmacokinetics in Parkinson disease; the study has completed.
-
CLINICAL_TRIALS trial_result · 2017-03-29Clinical Trial Update: Effect of Food on BIA 6-512 (Trans-resveratrol) [Phase 1]
A Phase 1 study update reports on the effect of food on exposure to BIA 6-512 (trans-resveratrol) in Parkinson's disease, and the trial stat…
-
CLINICAL_TRIALS trial_result · 2017-03-29Clinical Trial Update: Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States [Phase 4]
A Phase 4 study evaluating the impact of carbidopa/levodopa/entacapone on quality of life in Parkinson's disease has completed and is not re…
-
CLINICAL_TRIALS trial_result · 2017-03-29Clinical Trial Update: Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve [Phase 4]
Phase 4 clinical trial update on dexmedetomidine and cognitive reserve with completed results related to perioperative cognitive function, d…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-03-28Clinical Trial Update: Tolerability and Steady-state Pharmacokinetics of BIA 6-512 [Phase 1]
Phase 1 study reports tolerability and steady-state pharmacokinetics of BIA 6-512 in Parkinson disease; trial completed.
-
CLINICAL_TRIALS trial_result · 2017-03-27Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease [Phase 1]
Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06649751 in Parkinson's disease has completed and…
-
CLINICAL_TRIALS trial_result · 2017-03-27Clinical Trial Update: Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics [Phase 1]
Phase 1 trial evaluating tolerability, safety, and pharmacokinetics of four single doses of BIA 6-512 (trans-resveratrol) and its effect on …
-
CLINICAL_TRIALS trial_result · 2017-03-27Clinical Trial Update: Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics [Phase 1]
Phase 1 pharmacokinetic study evaluating rising single doses of BIA 6-512 and their effect on levodopa pharmacokinetics in Parkinson disease…
-
CLINICAL_TRIALS trial_result · 2017-03-24Clinical Trial Update: Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease [Phase 1, Phase 2]
Clinical trial update describing a Phase 1/2 study on the respiratory kinematics of cough in healthy older adults and people with Parkinson'…
-
CLINICAL_TRIALS trial_result · 2017-03-23Clinical Trial Update: Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa [Phase 3]
A Phase 3 trial evaluating an investigational Parkinson's disease therapy in patients not well controlled on L-dopa has completed, with spon…
-
CLINICAL_TRIALS trial_result · 2017-03-22Clinical Trial Update: Caffeine as a Therapy for Parkinson's Disease [Phase 3]
This update reports the completion of a Phase 3 clinical trial evaluating caffeine as a therapy for Parkinson's disease.
-
FDA approval · 2017-03-21FDA Approved: XADAGO — Original Application (MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc.)
FDA approved XADAGO (safinamide mesylate) in an Original Application for Parkinson's disease. The applicant/manufacturer is MDD US Operation…
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease [Phase 1]
A Phase 1 study of LY3154207 in healthy participants and individuals with Parkinson's disease has completed.
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: Variable Frequency Stimulation of Subthalamic Nucleus for Freezing of Gait in Parkinson's Disease [Phase 1]
Phase 1 study evaluating variable frequency stimulation of the subthalamic nucleus for freezing of gait in Parkinson's disease has completed…
-
CLINICAL_TRIALS research · 2017-03-17Clinical Trial Update: Singing in Groups for Parkinson's Disease; A Pilot Study of Group Singing Therapy for PD-related Voice/Speech Impairment [NA]
This clinical trial update reports on a pilot study of group singing therapy for voice and speech impairment in Parkinson's disease, sponsor…
-
CLINICAL_TRIALS trial_result · 2017-03-16Clinical Trial Update: Dance Exercise as Novel Complementary Therapy for Parkinson's Disease
A clinical trial investigating dance-based exercise as a complementary therapy for Parkinson's disease has completed.
-
CLINICAL_TRIALS trial_result · 2017-03-15Clinical Trial Update: Extended Long-Term Safety Study of KW-6500 [Phase 3]
This document provides an update on the extended long-term safety study of KW-6500 in Parkinson's disease, a Phase 3 trial that has complete…
-
CLINICAL_TRIALS trial_result · 2017-03-15Clinical Trial Update: Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease [Phase 3]
A Phase 3 long-term safety study of KW-6500 in Parkinson's disease has completed; this entry provides an update on the trial status.
-
CLINICAL_TRIALS trial_result · 2017-03-10Clinical Trial Update: Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease [Phase 4]
Phase 4 trial evaluating safety and efficacy of botulinum toxin A (BotoxA) for neurogenic bladder in Parkinson's disease has completed with …
-
CLINICAL_TRIALS trial_result · 2017-03-08Clinical Trial Update: Translation and Validation of BELA-p-K for QoL Evaluation in PD Patients
A completed clinical trial evaluating the translation and validation of the BELA-p-K quality-of-life instrument for patients with Parkinson …
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500 [Phase 3]
A Phase 3 placebo-controlled, double-blind crossover study of KW-6500 for Parkinson's disease has completed.
-
CLINICAL_TRIALS research · 2017-03-03Clinical Trial Update: Motor, Non-motor and Genetic Determinants of Progression in Parkinson's Disease: A Mexican Multicenter Cohort Study
This completed Mexican multicenter cohort study investigates motor, non-motor, and genetic determinants of progression in Parkinson's diseas…
-
CLINICAL_TRIALS trial_result · 2017-03-01Clinical Trial Update: Parkinsonics: A Controlled Study of Group Singing in Parkinson Disease [Phase 2]
Phase 2 controlled trial investigating group singing in Parkinson disease has completed.
-
FDA approval · 2017-02-28FDA Approved: ROPINIROLE — Original Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s generic ropinirole under an Original Application (ANDA 204022) for indications including Parkinson's d…